Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ZyGEM to Commercialize DNA Detection and Testing Platform

By LabMedica International staff writers
Posted on 07 Jun 2010
ZyGEM Corp. More...
Ltd. (Hamilton, New Zealand; and Solana Beach, CA, USA) has acquired MicroLab Diagnostics Inc., a private company developing microfluidic devices for rapid DNA testing. ZyGEM will market products integrating its DNA extraction, reagents, and detection assays with microfluidic chip technology developed by MicroLab, which will operate as a business unit of the new company.

MicroLab's miniaturization of the entire DNA testing process within a single closed system significantly reduces the amount of sample and reagents that are needed, while virtually eliminating the chances for handling error or contamination. The integrated new products will dramatically decrease the time, complexity, and cost of conducting DNA testing and have transformational potential in a broad range of applications.

The ZyGEM/MicroLab system is compact, easy-to-use, and cost-effective, making it suitable for use both in the laboratory and out in the field. It can perform multiplexed analyses, and it can also be configured for specific applications. Portable handheld versions are in development.

A prototype of the new system produced accurate DNA results in less than an hour, comparable to results obtained with current technology requiring three separate instruments and 5 to 10 hours. The new technology has the potential for applications where accuracy, speed, and ease-of-use are critical, including, point-of-care diagnostics, forensics, biodefense, and food pathogen testing.

ZyGEM intends to continue to expand sales of its proprietary assays and kits that use a thermophilic enzyme to extract DNA or RNA from a wide range of sample types using a single, closed-tube system.

Under the terms of the agreement, the new company will be called ZyGEM and will be headquartered in Charlottesville, Virginia (USA).

Dr. James Landers, cofounder of MicroLab Diagnostics and CSO of the new company, noted, "ZyGEM brings us DNA extraction and detection technology that is an ideal fit with our microchips, enabling us to achieve a seamless sample-to-answer solution with broad market applicability. It also brings us commercial expertise and a global network of distributors and partners.

Related Links:

ZyGEM Corp. Ltd.
MicroLab Diagnostics Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.